Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Arcutis Biotherapeutics, Inc.'s quarterly P/E stands at 55.8x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -207.46 | 55.85 | 84.45 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 8.84 | 7.60 | 6.31 | 5.46 | 7.48 | 5.90 | 6.46 | 9.30 | 5.55 | 5.53 | 2.15 | 28.20 | 60.49 |
| — | +28.8% | -2.3% | -41.3% | +34.8% | +6.8% | +200.3% | -67.0% | -90.8% | -92.7% | -99.4% | — | — | |
| P/B Ratio | 18.11 | 20.79 | 15.85 | 12.81 | 13.82 | 10.70 | 7.38 | 6.16 | 4.89 | 3.37 | 7.02 | 7.27 | 4.82 |
| — | +94.4% | +114.7% | +108.0% | +182.4% | +217.1% | +5.2% | -15.3% | +1.6% | -21.7% | +74.1% | +29.7% | +25.6% | |
| P/FCF | — | 37.61 | — | 1809.45 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 49.65 | 70.74 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 53.06 | 60.87 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Arcutis Biotherapeutics, Inc.'s operating margin was 14.2% in Q4 2025, up 5.6 pp QoQ and up 24.9 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -8.1% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.2% | 91.0% | 91.2% | 90.8% | 86.6% | 90.3% | 87.7% | 88.8% | 93.4% | 83.4% | 96.9% | 85.0% | 71.8% |
| — | +0.7% | +4.0% | +2.3% | -7.3% | +8.3% | -9.5% | +4.4% | +30.0% | -0.3% | +54.1% | — | — | |
| Operating Margin | -3.3% | 14.2% | 8.6% | -17.9% | -37.3% | -10.7% | -87.3% | -162.3% | -63.8% | -452.2% | -96.8% | -1286.4% | -2742.4% |
| — | +232.8% | +109.8% | +89.0% | +41.6% | +97.6% | +9.9% | +87.4% | +97.7% | +80.4% | +99.3% | — | — | |
| Net Margin | -4.3% | 13.4% | 7.5% | -19.5% | -38.1% | -15.1% | -92.8% | -169.6% | -71.4% | -490.0% | -117.5% | -1367.8% | -2867.2% |
| — | +188.9% | +108.0% | +88.5% | +46.7% | +96.9% | +21.0% | +87.6% | +97.5% | +79.9% | +99.2% | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.3% | 10.0% | 5.0% | -11.3% | -16.7% | -6.9% | -24.2% | -25.4% | -22.6% | -97.9% | -70.4% | -64.5% | -45.7% |
| — | +245.8% | +120.6% | +55.7% | +26.0% | +93.0% | +65.6% | +60.5% | +50.6% | -226.6% | -52.3% | -114.8% | -95.7% | |
| ROA | -4.1% | 4.3% | 2.0% | -4.6% | -7.2% | -2.7% | -9.4% | -11.3% | -8.6% | -20.9% | -14.6% | -20.3% | -19.2% |
| — | +257.7% | +121.8% | +59.8% | +16.2% | +86.9% | +35.5% | +44.1% | +55.1% | -39.0% | +45.2% | +0.0% | -15.5% | |
| ROIC | -5.2% | 7.3% | 3.2% | -5.8% | -9.3% | -2.7% | -10.9% | -13.7% | -10.6% | -26.2% | -17.1% | -22.7% | -18.4% |
| — | +372.3% | +129.4% | +57.4% | +12.7% | +89.8% | +36.4% | +39.8% | +42.5% | -91.1% | +34.4% | -8.6% | -5.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Arcutis Biotherapeutics, Inc.'s Debt/EBITDA ratio is 0.3x, down from 12.5x last quarter — comfortably within a safe range. The current ratio has weakened 23.6% YoY to 3.17x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.72 | 0.79 | 0.78 | 0.70 | 1.33 | 1.11 | 0.92 | 2.32 | 4.39 | 2.54 | 1.46 |
| — | -95.3% | -45.8% | -28.8% | -15.5% | -69.8% | -69.7% | -56.1% | -36.9% | +140.3% | +489.4% | +534.0% | +374.4% | |
| Debt / EBITDA | — | 0.32 | 12.52 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.17 | 3.17 | 3.50 | 3.20 | 3.55 | 4.15 | 2.46 | 8.46 | 9.89 | 7.08 | 6.72 | 8.43 | 9.93 |
| — | -23.6% | +42.4% | -62.2% | -64.1% | -41.5% | -63.4% | +0.4% | -0.4% | -38.8% | -49.8% | -21.6% | -8.8% | |
| Quick Ratio | 2.99 | 2.99 | 3.28 | 3.04 | 3.37 | 3.97 | 2.38 | 8.19 | 9.61 | 6.80 | 6.39 | 8.14 | 9.70 |
| — | -24.5% | +37.9% | -62.8% | -65.0% | -41.7% | -62.8% | +0.7% | -0.9% | -40.2% | -51.9% | -24.3% | -10.9% | |
| Interest Coverage | -1.01 | 6.13 | 2.78 | -4.82 | -8.23 | -1.37 | -5.87 | -6.69 | -4.23 | -7.88 | -4.88 | -9.08 | -10.83 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArcutis Biotherapeutics, Inc.'s current P/E is -207.5x. The average P/E over the last 2 quarters is 70.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcutis Biotherapeutics, Inc.'s current operating margin is -3.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcutis Biotherapeutics, Inc.'s business trajectory between earnings reports.